ResMed Inc.'s Stock Analysis

ResMed Reports 11% Revenue Growth and Declares Dividend

ResMed announced its financial results for the quarter ending March 31, 2026, showing an 11% increase in reported revenue compared to the previous year. The company also experienced a 290 basis point expansion in non-GAAP gross margin and a 21% rise in earnings per share, indicating strong operational performance driven by demand for its products.

Additionally, ResMed's board of directors declared a quarterly cash dividend of $0.60 per share, with a record date of May 14, 2026, and payment scheduled for June 18, 2026. The ex-dividend date is set for May 13, 2026. Shareholders on the New York Stock Exchange will receive the dividend in U.S. currency, while holders of CHESS Depositary Interests on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date.

Apr 30, 2026 16:06:30

ResMed CFO Retirement and Successor Appointment Announced

ResMed Inc. announced that Brett Sandercock, the Chief Financial Officer, will retire on May 4, 2026, after 27 years with the company, including 20 years as CFO. Following his retirement, Sandercock will serve as a Special Advisor to the CEO until the end of 2027, maintaining his salary and benefits during this period. The company has appointed Aaron Bloomer as the new CFO, effective May 4, 2026. Bloomer previously held senior finance roles at Exact Sciences, Baxter International, and 3M, and is expected to bring substantial experience in financial leadership and operational growth to ResMed.

Aaron Bloomer's compensation package includes a base salary of $725,000, a sign-on bonus of $150,000, and an annual short-term cash incentive bonus target of 80% of his base salary. Additionally, he will receive a long-term performance equity grant valued at $3.3 million upon joining the company, with a focus on aligning his interests with shareholder value creation. ResMed reiterated its fiscal year 2026 outlook, maintaining key financial targets for gross margin, SG&A expenses, and R&D expenses.

Apr 30, 2026 16:10:25

ResMed Declares Quarterly Dividend and Reports Q2 Financial Results

On January 29, 2026, ResMed announced a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026, and a payment date of March 19, 2026. The ex-dividend date is set for February 11, 2026. The dividend will be paid in U.S. currency to common stockholders on the New York Stock Exchange, while holders of CHESS Depositary Instruments on the Australian Securities Exchange will receive the equivalent amount in Australian currency. ResMed also received a waiver from the ASX’s settlement rules allowing the deferral of conversions between its common stock and CDI registers during this period.

In its financial results for the quarter ended December 31, 2025, ResMed reported an 11% year-over-year revenue growth and a 310 basis points increase in non-GAAP gross margin. The company experienced mid-teens growth in non-GAAP earnings per share (EPS) due to strong demand for its sleep and respiratory care devices. ResMed's digital health ecosystem is expanding its reach across more than 140 countries, contributing to its operational performance and future investment plans in innovation and global access to healthcare.

Jan 29, 2026 16:05:45

ResMed Stockholder Approves Key Amendments to Incentive Plans

At the Annual Meeting held on November 19, 2025, ResMed's stockholders approved significant amendments to the company's 2009 Incentive Award Plan and the 2018 Employee Stock Purchase Plan. The amendments to the 2009 Plan include an increase of 2,400,000 shares reserved for issuance and the elimination of a fixed term, while the ESPP Amendment increases shares by 3,000,000 and also removes the fixed term. Both amendments allow for the grant of stock options intended to be tax-qualified under Section 423 of the Code.

Additionally, the board of directors has been reduced from twelve to eleven members following Richard Sulpizio's decision not to seek re-election. Stockholders also ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, and approved the advisory compensation for named executive officers. These decisions could impact the company's governance and compensation structures, influencing investor sentiment.

Nov 20, 2025 16:30:26

ResMed Reports 9% Revenue Growth and Declares Dividend

ResMed announced its financial results for the quarter ending September 30, 2025, reporting a 9% increase in revenue year-over-year. The company achieved a 280 basis point expansion in non-GAAP gross margin, leading to a 16% growth in non-GAAP earnings per share. These results reflect the company's ongoing strategy to enhance home healthcare solutions through innovative products and technology.

Additionally, ResMed's board of directors declared a quarterly cash dividend of $0.60 per share, with a record date of November 13, 2025, and a payment date set for December 18, 2025. The ex-dividend date is November 12, 2025. The dividend will be distributed in U.S. currency for common stockholders on the New York Stock Exchange, while holders of CHESS Depositary Interests on the Australian Securities Exchange will receive an equivalent amount in Australian currency.

Oct 30, 2025 16:06:11

ResMed Elects New Director and Announces Board Retirement

On August 15, 2025, ResMed Inc. announced the election of Nicole Mowad-Nassar to its board of directors. Mowad-Nassar, who is currently the Senior Vice President at AbbVie Inc., brings extensive experience in commercial strategy and operations from her previous roles. She will serve on the Compensation and Leadership Development Committee and will be up for reelection at the 2025 Annual Meeting of Stockholders scheduled for November 19, 2025.

Additionally, Richard Sulpizio, a board member since 2005, will retire and not stand for reelection at the upcoming annual meeting. His departure marks the end of a two-decade tenure during which he contributed to various board committees, including the Compensation Committee. ResMed acknowledged Sulpizio's significant contributions to the company and its governance.

Aug 18, 2025 16:20:28

ResMed Chief Commercial Officer to Resign Effective August 2025

Bobby Ghoshal, the Chief Commercial Officer of ResMed, has announced his resignation effective August 1, 2025. He will be leaving to take on a role as Chief Operating Officer at a software company that operates in a non-competitive industry.

This leadership change may impact ResMed's operations, particularly within its residential care software business. Investors may want to monitor how this transition affects the company's strategic direction and performance in the coming months.

Jul 31, 2025 18:30:21

ResMed Declares Quarterly Dividend and Reports Fiscal Results

On July 31, 2025, ResMed Inc. announced a quarterly cash dividend of $0.60 per share, with a record date of August 14, 2025, and payment scheduled for September 18, 2025. The ex-dividend date is set for August 13, 2025. The company has also received a waiver from the ASX’s settlement operating rules to defer processing conversions between its common stock and CHESS Depositary Interests for the specified dates.

In its financial results for the fourth quarter ended June 30, 2025, ResMed reported a 10% increase in revenue compared to the prior year, along with a 230 basis point expansion in non-GAAP gross margin and a 23% growth in non-GAAP earnings per share. The company attributed this growth to strong global demand for its sleep and breathing health devices and an expanding digital health ecosystem.

Jul 31, 2025 16:05:17

Resmed Reports 8% Revenue Growth in Q3 Fiscal 2025

Resmed Inc. announced its financial results for the third quarter of fiscal year 2025, reporting an 8% increase in revenue to $1.3 billion compared to the same period last year. The company achieved a 14% rise in income from operations and a 140 basis point improvement in gross margin, reaching 59.3%. Operating cash flow for the quarter was $579 million, with diluted earnings per share at $2.48. The growth was attributed to strong demand for sleep devices and solid performance in the Residential Care Software business.

In addition to financial results, Resmed introduced its home sleep apnea test, NightOwl™, across the U.S. and shared findings from its Global Sleep Survey highlighting a significant global sleep crisis. The company declared a quarterly cash dividend of $0.53 per share, with a record date of May 8, 2025. Resmed's ongoing efforts include enhancing brand visibility and addressing the healthcare needs of individuals with sleep and breathing health issues, indicating a commitment to maintaining growth in its market.

Apr 23, 2025 16:05:31

ResMed Reports $1.3 Billion Revenue in Q2 Fiscal 2025

ResMed Inc. reported a 10% increase in revenue, reaching $1.3 billion, and a significant 52% rise in operating profit for the second quarter of fiscal year 2025. The company also noted a gross margin improvement of 300 basis points to 58.6% and an operating cash flow of $309 million. Non-GAAP diluted earnings per share increased by 29% to $2.43, driven by strong sales growth and operational efficiencies. Additionally, the company announced a quarterly cash dividend of $0.53 per share and highlighted its commitment to expanding operations in Singapore.

On the downside, selling, general, and administrative expenses rose by 9% on a constant currency basis, primarily due to increased employee-related costs. Although operating income increased significantly, it is important to note that the prior year's results included restructuring charges, which may have impacted the year-over-year comparison. The company also faced challenges in managing expenses while continuing to invest in growth initiatives, pointing to a need for careful financial management moving forward.

Jan 30, 2025 16:05:28